text: Much of Jansens oeuvre uses in silico' methods to study receptor biology, drug design, and drug-protein interactions. An early study (2000) while she was employed at Chiron looked at conformations of the anti-cancer treatment Taxol in nonpolar environments.
  In a 2012 commentary for Future Medicinal Chemistry, Jansen led a team of distinguished computational chemists in a call to action, namely that standardized data sets be used across the industry, and that sharing program code between groups at different companies and institutions should be mandated.
  A 2017 open-access study in PLoS One related some of Novartis' work - spearheaded by Jansen - to study the oncogenic protein RAS through inhibitors that targeted its inactive conformations.